Watchdog Group Revives Concerns Over Symlin Dosing Instructions
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA's internal review of the dosing instructions for Amylin's antidiabetic Symlin likely will revisit dosing-related concerns first identified during its NDA review